J&J Pits 5% Minoxidil Rogaine For Women Against ‘Cosmetic, Quick Fixes’
This article was originally published in The Rose Sheet
Firm’s McNeil-PPC subsidiary has patent exclusivity for Women’s Rogaine with the higher concentration of minoxidil through February 2017, tightening its grip on a market that cosmetics firms have struggled to penetrate effectively in the United States. According to a brand consultant and dermatologist, the new Rogaine offering actually helps regrow hair rather than merely “masking” the issue.
You may also be interested in...
CEO Matthew Farrell says just 1% to 3% of C&D's sales currently are online, but the firm is learning new tricks from its recently acquired Toppik Hair Building Fibers brand, which generates around a third of its sales through e-commerce platforms. Meanwhile, the "serial acquirer" has an eye peeled for new category opportunities.
Skin-care and OTC product sales helped propel J&J’s consumer business in the fiscal 2015 first quarter, but currency headwinds dragged on results. CFO Dominic Caruso says the firm is stocking shelves more consistently with previously recalled OTCs, but FDA still needs to sign off on J&J’s remediation work before it returns to full manufacturing capacity, and the agency will monitor the company for a further five years under a 2011 consent decree.
With FDA scrutinizing the marketplace for cosmetics promoted as drugs, and a clear cautionary statement from the agency about topical products marketed as hair growers or hair-loss preventers, beauty firms have little choice but to incorporate approved OTC drug ingredients in such products. P&G’s professional hair-care brand NIOXIN has done just that with its new Advanced Thinning range featuring minoxidil.